Valuation: Axsome Therapeutics, Inc.

Market Cap 12.2B 10.66B 9.86B 9.05B 17.12B 1,175B 17.42B 118B 46.2B 574B 45.81B 44.8B 1,982B P/E 2026 *
-115x
P/E 2027 * 42.3x
Enterprise Value 12.09B 10.57B 9.77B 8.97B 16.97B 1,165B 17.26B 117B 45.78B 569B 45.39B 44.4B 1,964B EV / Sales 2026 *
12.3x
EV / Sales 2027 * 7.4x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.30%
1 week+0.42%
Current month-4.08%
1 month-6.89%
3 months+24.23%
6 months+27.25%
Current year+28.55%
1 week 224.7
Extreme 224.7001
240.86
1 month 224.7
Extreme 224.7001
260.19
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/11/26 Sell

Director

-286 0.0006%
6/10/26 Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%+0.42%+109.18%+220.39% 12.2B
+0.89%+3.77%+25.38%-4.44% 69.07B
+0.21%+0.38%+36.78%+196.91% 51.77B
+0.94%+39.60%+39.60%+39.60% 43.63B
+1.12%+0.35%-50.35%-52.35% 40.89B
+1.89%+8.03%+67.18%-22.72% 30.84B
-1.04%-7.94%+95.19%-48.74% 25.06B
+2.04%+2.08%+72.82%+95.06% 23.3B
-5.57%-0.84%-0.17%+182.38% 20.92B
-1.14%-2.67%+67.25%+122.84% 16.71B
Average -0.10%-1.88%+46.29%+72.89% 33.44B
Weighted average by Cap. +0.30%-1.48%+35.68%+54.79%

Financials

2026 *2027 *
Net sales 979M 856M 791M 726M 1.37B 94.33B 1.4B 9.44B 3.71B 46.06B 3.68B 3.6B 159B 1.59B 1.39B 1.29B 1.18B 2.24B 154B 2.28B 15.37B 6.04B 75.04B 5.99B 5.86B 259B
Net income -107M -93.85M -86.79M -79.64M -151M -10.35B -153M -1.04B -407M -5.05B -403M -394M -17.44B 310M 271M 251M 230M 435M 29.88B 443M 2.99B 1.17B 14.59B 1.16B 1.14B 50.37B
Net Debt -111M -96.76M -89.48M -82.11M -155M -10.67B -158M -1.07B -419M -5.21B -416M -407M -17.98B -394M -344M -318M -292M -553M -37.95B -562M -3.8B -1.49B -18.53B -1.48B -1.45B -63.97B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-17 $235.69 -0.57% 86,759
26-07-16 $237.04 -0.21% 639,658
26-07-15 $237.53 +0.96% 838,870
26-07-14 $235.26 +3.06% 482,756
26-07-13 $228.28 -2.36% 843,010
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
237.04USD
Average target price
280.39USD
Spread / Average Target
+18.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock